RESEARCH
CLINICAL / EPIDEMIOLOGICAL RESEARCH
Blood Pressure
Systolic Blood Pressure Intervention Trial (SPRINT)
Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data
Principal Investigator
Paul Drawz, MD
Program Manager
Nayanjot Kaur Rai, MPH, BDS
rai00041@umn.edu
Diabetic Kidney Disease
Phase 2a Trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Principal Investigator
Patrick Nachman, MD
Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Transplantation Research (Kidney and Pancreas)
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Principal Investigator
Rasha El-Rifai, MD
Co-Investigator
Richard Spong, MD
Study Coordinator
Ghislaine Feussom, MPH
feuss001@umn.edu
Phase 3
A Randomized, Controlled, Multi-Center, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus and Mycophenolate-Based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1)
Principal Investigator
Erik Finger, MD, PhD
Co-Investigator
Rasha El-Rifai, MD
Study Coordinator
Marcia Brott
brott001@umn.edu
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Principal Investigator
Adam Bregman, MD, MBA
Study Coordinator
Ghislaine Feussom, MPH
feuss001@umn.edu
Cf-DNA Assay During Treatment of Acute Rejection-Pilot Study
Principal Investigator
Arthur Matas, MD
Co-Investigators
Adam Bregman, MD, MBA
Study Coordinators
Marcia Brott
brott001@umn.edu
Alyssa Nelson, BS
nels9147@umn.edu
Anti-GBM
Phase 3 Trial
A Phase 3 open- label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)
Principal Investigator
Patrick Nachman, MD
Co-Investigators
Nattawat Klomjit, MD
Sahar Koubar, MBBS
Katie Pendleton, MD
Sami Safadi, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Phase 2a Trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Principal Investigator
Patrick Nachman, MD
Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
IGA NEPHROPATHY
Phase 3 Trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Principal Investigator
Patrick H. Nachman, MD
Co-Investigators
Surabhi Thakar, MD
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Joy Bolea, RN, MS
jbolea@umn.edu
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy
Principal Investigator
Sahar Koubar, MBBS
Co-Investigators
Nattawat Klomjit, MD
Patrick H. Nachman, MD
MEMBRANOUS NEPHROPATHY
Phase 2 Trial
Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)
Principal Investigator
Patrick Nachman, MD
Co-Investigator
Surabhi Thakar, MD
Katti Woerner, MD
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
NEPHROTIC SYNDROME
The Nephrotic Syndrome Study Network (NEPTUNE)
Principal Investigator
Patrick Nachman, MD
Co-Principal Investigator
Michelle Rheault, MD
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Phase 2a Trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Principal Investigator
Patrick Nachman, MD
Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase 3 Trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)
Principal Investigator
Surabhi Thakar, MD
Co-Investigators
Patrick Nachman, MD
Katti Woerner, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
A Phase 2a Randomized Placebo-Controlled Double-Blind Multicenter Trial of VIB4920 for Active Lupus Nephritis (ITN091AI)
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Joy Bolea, RN, MS
jbolea@umn.edu
MINNESOTA GLOMERULAR DISEASE PROGRAM
To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to clinical trials. Learn More
MINNESOTA MULTIDISCIPLINARY VASCULITIS PROGRAM
To provide patients with glomerular disease with expert, individualized care and access to clinical trials. Learn More
Glomerular Diseases & Vasculitis Research
Programs
StudyFinder is a University of Minnesota website that displays a searchable listing of studies, which are extracted from ClinicalTrials.gov. At StudyFinder you can explore University health studies currently seeking participants.
Clinicaltrials.gov is a database of privately and publicly funded clinical studies conducted around the world.